NCCN Updates Prostate Cancer Early Detection Guidelines With Biomarker Information

The National Comprehensive Cancer Network has updated its guidelines on early detection of prostate cancer to include more specific language about how often men with BRCA mutations should be screened and the potential utility of certain biomarkers for determining high-grade cancer risk. 

The updated guidelines now specify that "it is reasonable for men with germline BRCA1/2 mutations to consider beginning shared decision making about PSA screening at age 40 and to consider screening at annual intervals rather than every other year."

The updated guidelines also note that certain biomarker tests may be "potentially informative" when trying to further define the probability of high-grade cancer.

INDUSTRY NEWS TAGS: Molecular Diagnostics

Share This Post:

Search Billing News

Billing News By TAG

Billing News By DATE